Kbp Biosciences Overview
- Founded
-
2007

- Status
-
Private
- Employees
-
33

- Latest Deal Type
-
Later Stage VC
- Investors
-
16
Kbp Biosciences General Information
Description
Operator of a biotechnology research and development company intended to treat unmet medical needs in cardiovascular, respiratory, inflammatory, and autoimmune diseases. The company's therapies are dedicated to the research, development, and commercialization of innovative medicines in areas of unmet medical need based on new drug development ideas and its own medicinal chemistry with clinical development and regulatory expertise, thereby enabling healthcare providers to treat patients suffering from cardio-renal and infectious diseases.
Contact Information
Website
www.kbpbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 116 Village Boulevard
- Suite 210
- Princeton, NJ 08540
- United States
+1 (609) 000-0000
Kbp Biosciences Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Later Stage VC | 01-Jan-2021 | 0000 | Completed | Generating Revenue | ||
1. Later Stage VC (Series A) | 05-Jan-2018 | 0000 | 0000 | 00000 | Completed | Generating Revenue |
Kbp Biosciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biotechnology research and development company intended to treat unmet medical needs in cardiovascular, re
Drug Discovery
Princeton, NJ
33
As of 2022
0000
0000000000 0
0000
Kbp Biosciences Competitors (38)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
NexImmune | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
000000 00000000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 000000 - 000 | 00000 |
00000000 | Venture Capital-Backed | Vienna, Austria | 00.000 | 0000000000 | 00.000 | |
0000000 | Formerly VC-backed | New Haven, CT | 000 | 00000 | 000000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Boston, MA | 0 | 00000 | 000000000 | 00000 |
Kbp Biosciences Patents
Kbp Biosciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20200392096-A1 | Compound acting as antibiotics | Pending | 10-Feb-2018 | 0000000000 | |
JP-2021513543-A | Antibacterial compound | Pending | 10-Feb-2018 | 0000000000 | |
EP-3750881-A1 | Compound acting as antibiotics | Pending | 10-Feb-2018 | 0000000000 | |
EP-3750881-A4 | Compound acting as antibiotics | Pending | 10-Feb-2018 | 0000000000 | |
CA-3090833-A1 | Compound acting as antibiotics | Pending | 10-Feb-2018 | C07D307/42 |
Kbp Biosciences Executive Team (14)
Kbp Biosciences Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Benjamin Qiu | Self | Board Member | 000 0000 |
Frederick Craves Ph.D | Bay City Capital | Board Member | 000 0000 |
Jin Wan | Kbp Biosciences | Board Member | 000 0000 |
Xiaoying Mai | Self | Board Member | 000 0000 |
Zhenhua Huang Ph.D | Kbp Biosciences | Founder & Executive Chairman | 000 0000 |
Kbp Biosciences Signals
Kbp Biosciences Investors (16)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
SDIC Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
3E Bioventures Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Advantech Capital Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
Bay City Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
CASH Capital | Venture Capital | Minority | 000 0000 | 000000 0 |